Product/Composition:- | Posaconazole Tablets |
---|---|
Strength:- | 300 mg |
Form:- | Delayed-Release Tablets |
Reference Brands:- | Noxafil(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Posaconazole delayed-release tablets inhibit fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis essential for fungal cell membranes. They provide broad-spectrum antifungal activity, improved absorption, and enhanced bioavailability. Benefits include effective prophylaxis and treatment of invasive fungal infections, with convenient dosing, making them vital for managing severe fungal diseases.
Posaconazole delayed-release tablets are approved in the EU and US for prophylaxis and treatment of invasive fungal infections. In the EU, MSD’s Noxafil is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continuous safety monitoring. For expert assistance with dossiers, regulatory submissions, and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory solutions. We facilitate efficient market access for posaconazole delayed-release tablets, ensuring adherence to European and American standards for safe, effective antifungal therapy.